Many patients stop taking the GLP-1s after six to nine months because theyre not seeing progress, said Dr
Key factors influencing whether weight loss injections may be appropriate include: Disease activity : Patients in stable remission may be better candidates than those experiencing active flares Location and extent of disease : Individuals with upper gastrointestinal or extensive small bowel involvement may face greater risks Presence of complications : Strictures, fistulas, or previous bowel resections may increase the risk of adverse effects Current medication regimen : While there are no known direct pharmacokinetic interactions with immunosuppressants or biologics, monitoring for overlapping gastrointestinal symptoms is important Nutritional status : Patients already experiencing malnutrition or deficiencies may not be suitable candidates NICE guidance on obesity management acknowledges that certain medical conditions require specialist input when considering pharmacological weight loss interventions
Concenos mejor Derecho Civil En Vessel Legal te asesoramos en contratos, herencias, reclamaciones de cantidad, responsabilidad civil, arrendamientos, propiedad y conflictos familiares, accidentes de trfico, etc
, -25% -GLP-1
Originally developed for diabetes management , these medications have been found to promote significant weight loss , making them a popular choice for individuals struggling with obesity and metabolic disorders
An overview of host-derived molecules that interact with gut microbiota
